



TALKMED GROUP LIMITED
(Company Registration No. 201324565Z)

FINANCIAL STATEMENT ANNOUNCEMENT FOR THE FIRST QUARTER ENDED 31 MARCH 2019

PART I - INFORMATION REQUIRED FOR ANNOUNCEMENTS OF QUARTERLY Q1 RESULTS

1(a) An income statement and statement of comprehensive income, or a statement of comprehensive income for the group, together with a comparative statement for the corresponding period of the immediately preceding financial year.

1(a)(i) The Directors of TalkMed Group Limited (the “**Company**”) are pleased to announce the unaudited consolidated results of the Company and its subsidiaries (collectively, the “**Group**”) for the first quarter ended 31 March 2019 (“**Q1 2019**”). The comparative period in this announcement is the first quarter ended 31 March 2018 (“**Q1 2018**”).

	Q1 2019 \$'000 (Unaudited)	Q1 2018 \$'000 (Unaudited)	Increase / (Decrease) %
The Group			
Revenue	16,974	12,068	40.7%
Other items of income			
Interest income	113	74	52.7%
Other income	29	34	(14.7%)
Other items of expense			
Employee benefits expense	(6,303)	(3,948)	59.7%
Cost of share-based payments to employees	(133)	(134)	(0.7%)
Operating lease expense	(9)	(434)	(97.9%)
Depreciation of right-of-use assets	(490)	-	N.M
Depreciation of plant and equipment	(355)	(120)	195.8%
Other operating expenses	(1,557)	(971)	60.4%
Share of results of associate	(276)	(219)	26.0%
Profit before tax	7,993	6,350	25.9%
Income tax expense	(1,738)	(1,292)	34.5%
Profit for the period	6,255	5,058	23.7%
Attributable to:			
Owners of the Company	6,980	5,381	29.7%
Non-controlling interests	(725)	(323)	124.5%
	6,255	5,058	23.7%

N.M = not meaningful

1(a)(i) The Directors of TalkMed Group Limited (the “**Company**”) are pleased to announce the unaudited consolidated results of the Company and its subsidiaries (collectively, the “**Group**”) for the first quarter ended 31 March 2019 (“**Q1 2019**”). The comparative period in this announcement is the first quarter ended 31 March 2018 (“**Q1 2018**”).

The Group	Q1 2019 \$'000 (Unaudited)	Q1 2018 \$'000 (Unaudited)	Increase / (Decrease) %
Other comprehensive income:			
Items that may be reclassified subsequently to profit or loss			
Foreign currency translation	50	-	N.M
Share of other reserve of associate	320	-	N.M
Other comprehensive income for the period, net of tax	370	-	N.M
Total comprehensive income for the period	6,625	5,058	31.0%
Attributable to:			
Owners of the Company	7,350	5,381	36.6%
Non-controlling interests	(725)	(323)	124.5%
	6,625	5,058	31.0%

N.M = not meaningful

1(a)(ii) The net profit attributable to owners of the Company includes the following charges:

The Group	Q1 2019 \$'000 (Unaudited)	Q1 2018 \$'000 (Unaudited)	Increase / (Decrease) %
Finance costs on unwinding of discount adjustment of loans to subsidiaries	(68)	(16)	325.0%
Finance costs on lease liabilities	(30)	-	N.M

N.M = not meaningful

1(b)(i) A statement of financial position (for the issuer and group), together with a comparative statement as at the end of the immediately preceding financial year.

	Group		Company	
	31/03/2019 \$'000 (Unaudited)	31/12/2018 \$'000 (Audited)	31/03/2019 \$'000 (Unaudited)	31/12/2018 \$'000 (Audited)
ASSETS				
Non-current assets				
Plant and equipment	5,668	4,227	-	-
Right-of-use assets	1,071	-	-	-
Investment in subsidiaries	-	-	7,321	7,188
Investment in associate	3,498	3,404	11,524	11,524
Loans to subsidiaries	-	-	7,751	7,649
Prepaid operating expenses	4	4	-	-
	10,241	7,635	26,596	26,361

1(b)(i) A statement of financial position (for the issuer and group), together with a comparative statement as at the end of the immediately preceding financial year.

	Group		Company	
	31/03/2019 \$'000 (Unaudited)	31/12/2018 \$'000 (Audited)	31/03/2019 \$'000 (Unaudited)	31/12/2018 \$'000 (Audited)
Current assets				
Inventories	464	282	-	-
Right-of-use assets	931	-	-	-
Prepaid operating expenses	610	648	26	25
Trade and other receivables	7,096	8,714	15,905	15,851
Cash and short-term deposits	82,551	73,993	879	1,057
	91,652	83,637	16,810	16,933
Total assets	101,893	91,272	43,406	43,294
EQUITY AND LIABILITIES				
Current liabilities				
Trade and other payables	2,196	1,980	14	3
Other liabilities	3,805	3,980	381	150
Lease liabilities	934	-	-	-
Income tax payable	8,502	6,775	-	-
	15,437	12,735	395	153
Net current assets	76,215	70,902	16,415	16,780
Non-current liabilities				
Other liabilities	100	87	-	-
Lease liabilities	1,080	-	-	-
Loans from non-controlling shareholder to subsidiaries	5,167	5,099	-	-
	6,347	5,186	-	-
Total liabilities	21,784	17,921	395	153
Net assets	80,109	73,351	43,011	43,141
Equity attributable to owners of the Company				
Share capital	22,273	22,273	22,273	22,273
Merger reserve	(2,311)	(2,311)	-	-
Share-based payments reserve	1,016	883	1,016	883
Other reserve	2,189	1,869	-	-
Foreign currency translation reserve	(445)	(495)	-	-
Retained earnings	58,527	51,547	19,722	19,985
	81,249	73,766	43,011	43,141
Non-controlling interests	(1,140)	(415)	-	-
Total equity	80,109	73,351	43,011	43,141
Total equity and liabilities	101,893	91,272	43,406	43,294

1(b)(ii) In relation to the aggregate amount of group's borrowings and debt securities, specify the following as at the end of current financial period reported on with comparative figures as at the end of the immediately preceding financial year:

(a) the amount repayable in one year or less, or on demand;
None

(b) the amount repayable after one year;
None

(c) whether the amounts are secured or unsecured; and
None

(d) details of any collaterals.
None

1(c) A statement of cash flows (for the group), together with a comparative statement for the corresponding period of the immediately preceding financial year.

The Group	Q1 2019 \$'000 (Unaudited)	Q1 2018 \$'000 (Unaudited)
Operating Activities		
Profit before tax	7,993	6,350
<u>Adjustments for:</u>		
Depreciation of plant and equipment	355	120
Depreciation of right-of-use assets	490	-
Cost of share-based payments	133	134
Finance costs on unwinding of discount adjustment of loans to subsidiaries	68	16
Finance costs on lease liabilities	30	-
Interest income	(113)	(74)
Share of results of associate	276	219
Operating cash flows before changes in working capital	<u>9,232</u>	<u>6,765</u>
Changes in working capital		
Increase in inventories	(182)	(60)
Increase in right-of-use assets	(2,492)	-
Decrease/(increase) in prepaid operating expenses	38	(44)
Decrease in trade and other receivables	1,528	2,730
Increase/(decrease) in trade and other payables	216	(216)
Decrease in other liabilities	(162)	(442)
Increase in lease liabilities	2,492	-
Net changes in working capital	<u>1,438</u>	<u>1,968</u>
Cash flows generated from operations	10,670	8,733
Interest received	203	197
Interest paid	(30)	-
Income tax paid	(11)	(1,500)
Net cash flows generated from operating activities	<u>10,832</u>	<u>7,430</u>
Investing Activities		
Purchase of plant and equipment	(1,796)	(96)
Net cash flows used in investing activities	<u>(1,796)</u>	<u>(96)</u>
Financing Activities		
Payment for principal portion of lease liabilities	(478)	-
Net cash flows used in financing activities	<u>(478)</u>	<u>-</u>
Net increase in cash and cash equivalents	8,558	7,334
Cash and cash equivalents at beginning of the period	73,993	71,051
Cash and cash equivalents at end of the period	<u>82,551</u>	<u>78,385</u>

1(d)(i) A statement (for the issuer and group) showing either (i) all changes in equity or (ii) changes in equity other than those arising from capitalisation issues and distributions to shareholders, together with a comparative statement for the corresponding period of the immediately preceding financial year.

The Group (Unaudited)	Share capital \$'000	Merger reserve \$'000	Share- based payments reserve \$'000	Other reserve \$'000	Foreign currency translation reserve \$'000	Retained earnings \$'000	Non- controlling interests \$'000	Total equity \$'000
Balance at 1 January 2019	22,273	(2,311)	883	1,869	(495)	51,547	(415)	73,351
Profit for the period	-	-	-	-	-	6,980	(725)	6,255
<u>Other comprehensive income</u>								
Foreign currency translation	-	-	-	-	50	-	-	50
Share of other reserve of associate	-	-	-	320	-	-	-	320
Other comprehensive income for the period, net of tax	-	-	-	320	50	-	-	370
Total comprehensive income for the period	-	-	-	320	50	6,980	(725)	6,625
<u>Contributions by owners</u>								
Share-based payments	-	-	133	-	-	-	-	133
Balance at 31 March 2019	22,273	(2,311)	1,016	2,189	(445)	58,527	(1,140)	80,109
Balance at 1 January 2018	22,273	(2,311)	346	2,006	(632)	50,647	181	72,510
Profit for the period, representing total comprehensive income for the period	-	-	-	-	-	5,381	(323)	5,058
<u>Contributions by owners</u>								
Share-based payments	-	-	134	-	-	-	-	134
Balance at 31 March 2018	22,273	(2,311)	480	2,006	(632)	56,028	(142)	77,702

1(d)(i) A statement (for the issuer and group) showing either (i) all changes in equity or (ii) changes in equity other than those arising from capitalisation issues and distributions to shareholders, together with a comparative statement for the corresponding period of the immediately preceding financial year.

The Company (Unaudited)	Share capital \$'000	Share-based payments reserve \$'000	Retained earnings \$'000	Total equity \$'000
Balance at 1 January 2019	22,273	883	19,985	43,141
Loss for the period, representing total comprehensive income for the period	-	-	(263)	(263)
<u>Contributions by owners</u>				
Share-based payments	-	133	-	133
Balance at 31 March 2019	22,273	1,016	19,722	43,011
Balance at 1 January 2018	22,273	346	20,447	43,066
Loss for the period, representing total comprehensive income for the period	-	-	(342)	(342)
<u>Contributions by owners</u>				
Share-based payments	-	134	-	134
Balance at 31 March 2018	22,273	480	20,105	42,858

1(d)(ii) Details of any changes in the company's share capital arising from rights issue, bonus issue, share buy-backs, exercise of share options or warrants, conversion of other issues of equity securities, issue of shares for cash or as consideration for acquisition or for any other purpose since the end of the previous period reported on. State the number of shares that may be issued on conversion of all the outstanding convertibles, if any, against the total number of issued shares excluding treasury shares and subsidiary holdings of the issuer, as at the end of the current financial period reported on and as at the end of the corresponding period of the immediately preceding financial year. State also the number of shares held as treasury shares and the number of subsidiary holdings, if any, and the percentage of the aggregate number of treasury shares and subsidiary holdings held against the total number of shares outstanding in a class that is listed as at the end of the current financial period reported on and as at the end of the corresponding period of the immediately preceding financial year.

There are no changes in the Company's share capital since 31 December 2018. As at 31 March 2019 and 31 March 2018, there were no treasury shares held by the Company and there were no subsidiary holdings.

1(d)(iii) To show the total number of issued shares excluding treasury shares as at the end of the current financial period and as at the end of the immediately preceding year.

	Number of ordinary shares	
	31/03/2019	31/12/2018
Total number of issued shares	1,314,286,000	1,314,286,000

1(d)(iv) A statement showing all sales, transfers, cancellation and/or use of treasury shares as at the end of the current financial period reported on.

There were no shares held as treasury shares as at 31 March 2019 and 31 December 2018.

1(d)(v) A statement showing all sales, transfers, cancellation and/or use of subsidiary holdings as at the end of the current financial period reported on.

There were no subsidiary holdings.

2. Whether the figures have been audited or reviewed and in accordance with which auditing standard or practice.

The figures have not been audited nor reviewed by our auditors.

3. Where the figures have been audited or reviewed, the auditors' report (including any qualifications or emphasis of a matter).

Not applicable.

4. Whether the same accounting policies and methods of computation as in the issuer's most recently audited annual financial statements have been applied.

Except for the adoption of the SFRS(I)s and Amendments to SFRS(I)s applicable for the financial period beginning on or after 1 January 2019 and as disclosed in paragraph 5 below, the same accounting policies and methods of computation have been applied. Except as disclosed in paragraph 5, the adoption of new SFRS(I)s and Amendments to SFRS(I)s did not have any effect on the financial performance or position of the Group and the Company.

5. If there are any changes in the accounting policies and methods of computation, including any required by an accounting standard, what has changed, as well as the reasons for, and the effect of, the change.

The accounting policies adopted are consistent with those of the previous financial year except in the current financial year, the Group has adopted all the new and revised standards which are effective for the financial period beginning on or after 1 January 2019. On adoption of SFRS(I) 16 *Leases*, the Group has recognised right-of-use assets of \$2.49 million and lease liabilities of \$2.49 million for its leases previously classified as operating leases as of 1 January 2019. Except for the adoption of SFRS(I) 16, the adoption of the other new standards that are effective on 1 January 2019 has no material impact on the financial statements.

6. Earnings per ordinary share of the group for the current financial period reported on and the corresponding period of the immediately preceding financial year, after deducting any provision for preference dividends.

The Group	Q1 2019 (Unaudited)	Q1 2018 (Unaudited)
Profit attributable to owners of the Company (\$'000)	6,980	5,381
Weighted average number of ordinary shares used in the computation of basic earnings per share	1,314,286,000	1,314,286,000
Basic earnings per share (cents)	0.53	0.41
Weighted average number of ordinary shares used in the computation of diluted earnings per share	1,314,798,335	1,314,798,335
Diluted earnings per share (cents)	0.53	0.41

7. **Net asset value (for the issuer and group) per ordinary share based on the total number of issued shares excluding treasury shares of the issuer at the end of the:-**
(a) current financial period reported on; and
(b) immediately preceding financial year.

	Group		Company	
	31/03/2019 (Unaudited)	31/12/2018 (Audited)	31/03/2019 (Unaudited)	31/12/2018 (Audited)
Net asset value attributable to owners of the Company (\$'000)	81,249	73,766	43,011	43,141
Net asset value per ordinary share at end of the financial period (cents) #	6.18	5.61	3.27	3.28

#The calculation of net asset value per ordinary share was based on 1,314,286,000 shares for all periods.

8. **A review of the performance of the group, to the extent necessary for a reasonable understanding of the group's business. It must include a discussion of the following:-**
- (a) any significant factors that affected the turnover, costs and earnings of the group for the current financial period reported on, including (where applicable) seasonal or cyclical factors; and**
- (b) any material factors that affected the cash flow, working capital, assets or liabilities of the group during the current financial period reported on.**

Performance Review

Revenue

The Group's revenue for Q1 2019 was \$16.97 million, an increase of \$4.90 million or 40.7% from \$12.07 million in Q1 2018. The increase was mainly attributed to the increase in the number of patient visits compared to the same corresponding period last year.

Other items of income

Interest income

Interest income increased by \$0.04 million or 52.7% from \$0.07 million in Q1 2018 to \$0.11 million in Q1 2019. The increase was mainly due to the higher interest earned on fixed deposits.

Other income

The Group's other income comprised government-paid childcare leave and government grants under the Productivity and Innovation Credit Scheme, Wage Credit Scheme, Temporary Employment Credit and Special Employment Credit (collectively, the "**Grants**").

Other income decreased by \$5,000 or 14.7% in Q1 2019. The decrease was mainly due to lower Grants received.

Performance Review (cont'd)

Other items of expense

Employee benefits expense

Employee benefits expense comprised remuneration paid to doctors, nurses as well as other support staff. These included salaries and wages, allowances, CPF contributions, bonuses and staff benefits.

Employee benefits increased by \$2.35 million or 59.7% from \$3.95 million in Q1 2018 to \$6.30 million in Q1 2019.

Cost of share-based payments to employees

Share-based payments to employees related mainly to the options and performance shares that were granted on 11 May 2017 under the Company's employee share option scheme and the performance share plan respectively.

Share-based payments to employees recorded in Q1 2019 amounted to \$0.13 million which was similar to the amount recorded in the corresponding period last year.

Operating lease expense

Operating lease expense decreased by \$0.42 million or 97.9% from \$0.43 million in Q1 2018 to \$0.01 million in Q1 2019. The decrease was due to the adoption of SFRS(I) 16 on 1 January 2019.

Depreciation of right-of-use assets

Following the adoption of SFRS(I) 16 on 1 January 2019, the Group recorded depreciation of right-of-use assets of \$0.49 million in Q1 2019.

Depreciation of plant and equipment

Depreciation of plant and equipment increased by \$0.24 million or 195.8% from \$0.12 million in Q1 2018 to \$0.36 million in Q1 2019. The increase was due to the purchase of plant and equipment in Q1 2019.

Other operating expenses

Other operating expenses comprised mainly advertising and marketing expenses, legal and professional fees, utilities and laboratory consumables and services.

Other operating expenses increased by \$0.59 million or 60.4% from \$0.97 million in Q1 2018 to \$1.56 million in Q1 2019. This increase was mainly due to the overhead expenses incurred by a subsidiary, CellVec Pte. Ltd. ("**CellVec**"), which was incorporated in August 2018.

Share of results of associate

The Group's share of loss after tax of its associate, Hong Kong Integrated Oncology Centre Holdings Limited was \$0.28 million in Q1 2019. This was an increase of \$0.06 million as compared to \$0.22 million in Q1 2018.

Performance Review (cont'd)

Income tax expense

Income tax expense increased by \$0.45 million or 34.5% from \$1.29 million in Q1 2018 to \$1.74 million in Q1 2019 due to higher profits in Q1 2019. The effective tax rate for Q1 2019 was 21.7% as compared to 20.3% in Q1 2018.

Profit after tax

The Group recorded profit after tax of \$6.26 million in Q1 2019 as compared to \$5.06 million in Q1 2018, an increase of \$1.20 million or 23.7%. This was mainly due to an increase in revenue offset by an increase in employee benefits expense and other operating expenses.

Review of the Group's financial position

Non-current assets

The Group's non-current assets comprised plant and equipment, right-of-use assets, investment in associate and prepaid operating expenses. Non-current assets increased by \$2.61 million which was attributable to the following:

- Increase in the carrying amount of plant and equipment of \$1.44 million;
- Increase in right-of-use assets of \$1.07 million; and
- Increase in the carrying amount of investment in associate of \$0.10 million which arose from the share of other reserve offset by the share of loss of associate.

Current assets

Current assets comprised inventories, right-of-use assets, prepaid operating expenses, trade and other receivables and cash and short-term deposits. Current assets increased by \$8.02 million which was attributable to the increase in inventories of \$0.18 million, right-of-use assets of \$0.93 million and cash and short-term deposits of \$8.56 million, offset by a decrease in prepaid operating expenses of \$0.04 million and trade and other receivables of \$1.61 million.

The increase in cash and short-term deposits was mainly attributable to cash flows from operating activities while the decrease in trade and other receivables was mainly due to receipts from trade debtors.

Current liabilities

Current liabilities comprised trade and other payables, other liabilities, lease liabilities and income tax payable. Current liabilities increased by \$2.70 million. Trade and other payables increased by \$0.22 million mainly due to higher trade payables. Lease liabilities increased by \$0.93 million with the adoption of SFRS(I) 16 on 1 January 2019. Income tax payable increased by \$1.73 million due to the income tax provision for Q1 2019. Other liabilities decreased by \$0.18 million due to lower accrued operating expenses

Non-current liabilities

Non-current liabilities comprised other liabilities, lease liabilities and loans from non-controlling shareholder to subsidiaries. Non-current liabilities increased by \$1.16 million mainly due to an increase in other liabilities of \$0.01 million, an increase in lease liabilities of \$1.08 million and the unwinding of discount adjustment of loans from a non-controlling shareholder to subsidiaries of \$0.07 million.

Review of the Group's financial position (cont'd)

Equity attributable to owners of the Company

The increase was mainly attributable to profits recognised during the period.

Non-controlling interests

This related to the:-

- (i) 43.0%, 48.7% and 65.8%⁽¹⁾ non-controlling interests' share in the net equity of Stem Med Pte. Ltd. ("**Stem Med**"), Stem Med Indonesia Pte. Ltd. and DrSG Cellular Wellness Pte. Ltd. ("**DrSG**") respectively;
- (ii) 25.0% non-controlling interests' share in the net equity of TalkMed Chongqing Pte. Ltd.; and
- (iii) 43.0% non-controlling interests' share in the net equity of CellVec.

Note:-

- (1) Stem Med owns 60.0% of DrSG. By virtue of the Company's 57.0% interest in Stem Med, the Company effectively owns 34.2% of DrSG and the remaining 65.8% falls within the definition of non-controlling interests.

Review of the Group's cash flows

Operating activities

Net cash flows from operating activities amounted to \$10.83 million. This comprised operating cash flows before changes in working capital of \$9.23 million, net changes in working capital of \$1.44 million and interest received of \$0.20 million, less interest paid of \$0.03 million and income tax paid of \$0.01 million.

The net decrease in working capital of \$1.44 million was mainly due to the following:

- Decrease in prepaid operating expenses of \$0.04 million;
- Decrease in trade and other receivables of \$1.53 million;
- Increase in trade and other payables of \$0.21 million; and
- Increase in lease liabilities of \$2.49 million.

These were partially offset by the following:

- Increase in inventories of \$0.18 million;
- Increase in right-of-use assets of \$2.49 million; and
- Decrease in other liabilities of \$0.16 million.

Investing activities

Net cash flows used in investing activities of \$1.80 million was attributable to the purchase of plant and equipment by CellVec.

Financing activities

Net cash flows used in financing activities amounted to \$0.48 million which was related to the payment for principal portion of lease liabilities.

Net increase in cash and cash equivalents

The above resulted in a net increase in cash and cash equivalents of \$8.56 million.

9. Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results.

Not applicable.

- 10. A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the group operates and any known factors or events that may affect the group in the next reporting period and the next 12 months.**

Our business is dependent to a large extent on the economic performance of Singapore and countries in South East Asia.

The Group is facing pressure on revenue from the competition arising from lower medical costs in our neighbouring countries.

- 11. If a decision regarding dividend has been made, the required information has been disclosed.**

(a) Any dividend declared or recommended for the current financial period reported on

The Company does not recommend or declare any dividend for the financial period ended 31 March 2019.

(b) Any dividend declared for the corresponding period of the immediately preceding financial year

Not applicable.

(c) The date the dividend is payable

Not applicable.

(d) The date on which Registrable Transfers received by the Company (up to 5.00 pm) will be registered before entitlements to the dividend are determined.

Not applicable.

- 12. If no dividend has been declared (recommended), a statement to that effect and the reason(s) for the decision.**

The Company generally reviews its dividend policy semi-annually. As such, no dividend has been declared or recommended for the financial period ended 31 March 2019.

- 13. If the Group has obtained a general mandate from the shareholders for IPTs, the aggregate value of such transactions as required under Rule 920(1)(a)(ii). If no IPT mandate has been obtained, a statement to that effect.**

The Group does not have a general mandate from its shareholders for Interested Person Transactions pursuant to Rule 920(1)(a)(ii).

- 14. Confirmation pursuant to Rule 720(1)**

TalkMed Group Limited confirms that undertakings under Rule 720(1) have been obtained from all directors and executive officers in the format set out in form Appendix 7H.

15. Confirmation pursuant to Rule 705(5)

The Board of Directors hereby confirms that to the best of their knowledge, nothing has come to their attention which may render the unaudited interim financial statements of the Group and the Company for the period ended 31 March 2019 to be false or misleading in any material aspect.

BY ORDER OF THE BOARD

Ang Peng Tiam
Chief Executive Officer
25 April 2019

This announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, Hong Leong Finance Limited (the "Sponsor"), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited (the "SGX-ST"). The Sponsor has not independently verified the contents of this announcement. This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr Tang Yeng Yuen, Vice President, Head of Corporate Finance at 16 Raffles Quay, #01-05 Hong Leong Building, Singapore 048581. Telephone number: (65) 6415 9886